Compare American States Water Company (AWR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Incyte Corporation — how do they compare? American States Water Company trades at $84.54 (market cap $3.33B), while Incyte Corporation trades at $115.02 (market cap $22.95B). The key difference: Incyte Corporation is far larger — about 6.9× American States Water Company's market cap, and American States Water Company pays a 2.37% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AWR | INCY | |
|---|---|---|
Market Cap | $3.33B | $22.95B |
Sector | Utilities | Health |
52-Week High | $85.05 | $118.52 |
52-Week Low | $70.10 | $67.38 |
Enterprise Value | $4.24B | $18.97B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $85.05, up 0.64% today, with a bullish technical signal from moving averages and strong profitability metrics including a 19.66% net income margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200 million ATM equity offering. The stock shows consistent dividend performance with a 71-year growth streak, though recent quarters saw mixed earnings results versus expectations.
Outlook remains stable with revenue growth to $679 million in 2026 and solid cash flow, but risks include regulatory pressures and interest rate sensitivity. Analysts are cautious with only 20% buy ratings. The stock offers defensive appeal but faces execution risks in a high-valuation environment.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
